These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 29348373)

  • 1. [Immunopathogenesis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)].
    Yamamura T; Ono H; Sato W
    Brain Nerve; 2018 Jan; 70(1):35-40. PubMed ID: 29348373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
    Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
    BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Evidence for an autoimmune disease.
    Sotzny F; Blanco J; Capelli E; Castro-Marrero J; Steiner S; Murovska M; Scheibenbogen C;
    Autoimmun Rev; 2018 Jun; 17(6):601-609. PubMed ID: 29635081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.
    Mensah F; Bansal A; Berkovitz S; Sharma A; Reddy V; Leandro MJ; Cambridge G
    Clin Exp Immunol; 2016 May; 184(2):237-47. PubMed ID: 26646713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In myalgic encephalomyelitis/chronic fatigue syndrome, increased autoimmune activity against 5-HT is associated with immuno-inflammatory pathways and bacterial translocation.
    Maes M; Ringel K; Kubera M; Anderson G; Morris G; Galecki P; Geffard M
    J Affect Disord; 2013 Sep; 150(2):223-30. PubMed ID: 23664637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome.
    Nagy-Szakal D; Williams BL; Mishra N; Che X; Lee B; Bateman L; Klimas NG; Komaroff AL; Levine S; Montoya JG; Peterson DL; Ramanan D; Jain K; Eddy ML; Hornig M; Lipkin WI
    Microbiome; 2017 Apr; 5(1):44. PubMed ID: 28441964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
    Cliff JM; King EC; Lee JS; Sepúlveda N; Wolf AS; Kingdon C; Bowman E; Dockrell HM; Nacul L; Lacerda E; Riley EM
    Front Immunol; 2019; 10():796. PubMed ID: 31057538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression.
    Maes M; Twisk FN; Ringel K
    Psychother Psychosom; 2012; 81(5):286-95. PubMed ID: 22832503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).
    Hardcastle SL; Brenu EW; Johnston S; Nguyen T; Huth T; Wong N; Ramos S; Staines D; Marshall-Gradisnik S
    BMC Immunol; 2015 Jun; 16():35. PubMed ID: 26032326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor sleep quality is associated with greater circulating pro-inflammatory cytokines and severity and frequency of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) symptoms in women.
    Milrad SF; Hall DL; Jutagir DR; Lattie EG; Ironson GH; Wohlgemuth W; Nunez MV; Garcia L; Czaja SJ; Perdomo DM; Fletcher MA; Klimas N; Antoni MH
    J Neuroimmunol; 2017 Feb; 303():43-50. PubMed ID: 28038892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic fatigue syndrome and the immune system: Where are we now?
    Mensah FKF; Bansal AS; Ford B; Cambridge G
    Neurophysiol Clin; 2017 Apr; 47(2):131-138. PubMed ID: 28410877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.
    Brenu EW; van Driel ML; Staines DR; Ashton KJ; Hardcastle SL; Keane J; Tajouri L; Peterson D; Ramos SB; Marshall-Gradisnik SM
    J Transl Med; 2012 May; 10():88. PubMed ID: 22571715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
    Rivas JL; Palencia T; Fernández G; García M
    Front Immunol; 2018; 9():1028. PubMed ID: 29867995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.
    Cabanas H; Muraki K; Staines D; Marshall-Gradisnik S
    Front Immunol; 2019; 10():2545. PubMed ID: 31736966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome.
    Maes M; Leunis JC
    Neuro Endocrinol Lett; 2014; 35(7):577-85. PubMed ID: 25617880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against ß2-adrenergic receptors.
    Wirth K; Scheibenbogen C
    Autoimmun Rev; 2020 Jun; 19(6):102527. PubMed ID: 32247028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of activation antigens on CD8+ T lymphocytes in Myalgic Encephalomyelitis/chronic fatigue syndrome: inverse associations with lowered CD19+ expression and CD4+/CD8+ ratio, but no associations with (auto)immune, leaky gut, oxidative and nitrosative stress biomarkers.
    Maes M; Bosmans E; Kubera M
    Neuro Endocrinol Lett; 2015; 36(5):439-46. PubMed ID: 26707044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
    Cabanas H; Muraki K; Eaton-Fitch N; Staines DR; Marshall-Gradisnik S
    Front Immunol; 2021; 12():687806. PubMed ID: 34326841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot Study of Natural Killer Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
    Huth TK; Brenu EW; Ramos S; Nguyen T; Broadley S; Staines D; Marshall-Gradisnik S
    Scand J Immunol; 2016 Jan; 83(1):44-51. PubMed ID: 26381393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
    Huth TK; Staines D; Marshall-Gradisnik S
    J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.